|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
427 a.a.
|
 |
|
|
|
|
|
|
|
419 a.a.
|
 |
|
|
|
|
|
|
|
124 a.a.
|
 |
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
|
PDB id:
|
 |
|
 |
| Name: |
 |
Cell cycle
|
 |
|
Title:
|
 |
Tubulin-colchicine-vinblastine: stathmin-like domain complex
|
|
Structure:
|
 |
Tubulin alpha chain. Chain: a, c. Tubulin beta chain. Chain: b, d. Rb3 stathmin-like domain 4. Chain: e. Synonym: stathmin-like protein b3, rb3-sld. Engineered: yes
|
|
Source:
|
 |
Bos taurus. Cattle. Organism_taxid: 9913. Organ: brain. Other_details: brain. Rattus norvegicus. Norway rat. Organism_taxid: 10116. Gene: stmn4.
|
|
Biol. unit:
|
 |
Pentamer (from
)
|
|
Resolution:
|
 |
|
4.10Å
|
R-factor:
|
0.212
|
R-free:
|
0.269
|
|
|
Authors:
|
 |
B.Gigant,C.Wang,R.B.G.Ravelli,F.Roussi,M.O.Steinmetz,P.A.Cur A.Sobel,M.Knossow
|
Key ref:
|
 |
B.Gigant
et al.
(2005).
Structural basis for the regulation of tubulin by vinblastine.
Nature,
435,
519-522.
PubMed id:
DOI:
|
 |
|
Date:
|
 |
|
08-Mar-05
|
Release date:
|
31-May-05
|
|
|
|
|
|
PROCHECK
|
|
|
|
|
Headers
|
 |
|
|
References
|
|
|
|
|
|
|
|
|
|
No UniProt id for this chain
|
|
|
|
|
|
|
|
|
 |
 |
|
 |
|
 |
|
 |
|
|
Gene Ontology (GO) functional annotation
|
|
|
|
 |
 |
 |
|
 |
 |
 |
 |
|
 |
|
Cellular component
|
protein complex
|
4 terms
|
 |
|
Biological process
|
intracellular signal transduction
|
6 terms
|
 |
|
Biochemical function
|
structural molecule activity
|
4 terms
|
 |
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
DOI no:
|
Nature
435:519-522
(2005)
|
|
PubMed id:
|
|
|
|
|
| |
|
Structural basis for the regulation of tubulin by vinblastine.
|
|
B.Gigant,
C.Wang,
R.B.Ravelli,
F.Roussi,
M.O.Steinmetz,
P.A.Curmi,
A.Sobel,
M.Knossow.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
Vinblastine is one of several tubulin-targeting Vinca alkaloids that have been
responsible for many chemotherapeutic successes since their introduction in the
clinic as antitumour drugs. In contrast with the two other classes of small
tubulin-binding molecules (Taxol and colchicine), the binding site of
vinblastine is largely unknown and the molecular mechanism of this drug has
remained elusive. Here we report the X-ray structure of vinblastine bound to
tubulin in a complex with the RB3 protein stathmin-like domain (RB3-SLD).
Vinblastine introduces a wedge at the interface of two tubulin molecules and
thus interferes with tubulin assembly. Together with electron microscopical and
biochemical data, the structure explains vinblastine-induced tubulin
self-association into spiral aggregates at the expense of microtubule growth. It
also shows that vinblastine and the amino-terminal part of RB3-SLD binding sites
share a hydrophobic groove on the alpha-tubulin surface that is located at an
intermolecular contact in microtubules. This is an attractive target for drugs
designed to perturb microtubule dynamics by interfacial interference, for which
tubulin seems ideally suited because of its propensity to self-associate.
|
|
|
|
|
| |
Selected figure(s)
|
|
|
| |
 |
 |
|
 |
|
 |
Figure 1.
Figure 1: The vinblastine-binding site. a, The location of
vinblastine in (Tc)[2]R. (Tc)[2]R-bound vinblastine (Vlb, cyan)
is shown as a space-filling model; the complex consists of
RB3-SLD and two tubulin  heterodimers,
with colchicine (Col, yellow) bound to the -subunits
at the interface with the -subunit.
b, Left: chemical formula of vinblastine. Right: [a]-weighted
F [obs] - F [calc] omit map of vinblastine-soaked (Tc)[2]R
crystals contoured at 3.5 (magenta)
overlapped with vinblastine; the difference electron density map
between a C12'-bromovinblastine soaked (Tc)[2]R crystal after a
low and a high dose of X-ray irradiation is shown in green
(contoured at 5.5 ).
c, Two perpendicular views of the vinblastine site. The labelled
structural elements belong to the two domains that, together
with a C-terminal helical hairpin, constitute the tubulin
subunits. Loop T5 is part of the N-terminal 1
tubulin nucleotide-binding domain. Helix H6 and loop H6 -H7 link
this domain to the intermediate domain. Helix H10, strand S9 and
loop T7 are part of the 2
tubulin intermediate domain. Loops T5 and T7 contact the
nucleotide in straight protofilaments.
|
 |
Figure 3.
Figure 3: Kinetics of vinblastine binding to (Tc)[2]R.
|
 |
|
|
|
| |
The above figures are
reprinted
by permission from Macmillan Publishers Ltd:
Nature
(2005,
435,
519-522)
copyright 2005.
|
|
| |
Figures were
selected
by the author.
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
A.Grafmüller,
and
G.A.Voth
(2011).
Intrinsic bending of microtubule protofilaments.
|
| |
Structure, 19,
409-417.
|
 |
|
|
|
|
 |
D.J.Edwards,
J.A.Hadfield,
T.W.Wallace,
and
S.Ducki
(2011).
Tubulin-binding dibenz[c,e]oxepines as colchinol analogues for targeting tumour vasculature.
|
| |
Org Biomol Chem, 9,
219-231.
|
 |
|
|
|
|
 |
H.Yang,
A.Ganguly,
S.Yin,
and
F.Cabral
(2011).
Megakaryocyte lineage-specific class VI β-tubulin suppresses microtubule dynamics, fragments microtubules, and blocks cell division.
|
| |
Cytoskeleton (Hoboken), 68,
175-187.
|
 |
|
|
|
|
 |
R.A.Stanton,
K.M.Gernert,
J.H.Nettles,
and
R.Aneja
(2011).
Drugs that target dynamic microtubules: A new molecular perspective.
|
| |
Med Res Rev, 31,
443-481.
|
 |
|
|
|
|
 |
A.Tripathi,
and
G.E.Kellogg
(2010).
A novel and efficient tool for locating and characterizing protein cavities and binding sites.
|
| |
Proteins, 78,
825-842.
|
 |
|
|
|
|
 |
C.M.Li,
Y.Lu,
S.Ahn,
R.Narayanan,
D.D.Miller,
and
J.T.Dalton
(2010).
Competitive mass spectrometry binding assay for characterization of three binding sites of tubulin.
|
| |
J Mass Spectrom, 45,
1160-1166.
|
 |
|
|
|
|
 |
D.Calligaris,
P.Verdier-Pinard,
F.Devred,
C.Villard,
D.Braguer,
and
D.Lafitte
(2010).
Microtubule targeting agents: from biophysics to proteomics.
|
| |
Cell Mol Life Sci, 67,
1089-1104.
|
 |
|
|
|
|
 |
E.Screpanti,
S.Santaguida,
T.Nguyen,
R.Silvestri,
R.Gussio,
A.Musacchio,
E.Hamel,
and
P.De Wulf
(2010).
A screen for kinetochore-microtubule interaction inhibitors identifies novel antitubulin compounds.
|
| |
PLoS One, 5,
e11603.
|
 |
|
|
|
|
 |
G.V.Schimizzi,
J.D.Currie,
and
S.L.Rogers
(2010).
Expression levels of a kinesin-13 microtubule depolymerase modulates the effectiveness of anti-microtubule agents.
|
| |
PLoS One, 5,
e11381.
|
 |
|
|
|
|
 |
G.Xu,
J.S.Paige,
and
S.R.Jaffrey
(2010).
Global analysis of lysine ubiquitination by ubiquitin remnant immunoaffinity profiling.
|
| |
Nat Biotechnol, 28,
868-873.
|
 |
|
|
|
|
 |
J.A.Smith,
L.Wilson,
O.Azarenko,
X.Zhu,
B.M.Lewis,
B.A.Littlefield,
and
M.A.Jordan
(2010).
Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability.
|
| |
Biochemistry, 49,
1331-1337.
|
 |
|
|
|
|
 |
M.Kavallaris
(2010).
Microtubules and resistance to tubulin-binding agents.
|
| |
Nat Rev Cancer, 10,
194-204.
|
 |
|
|
|
|
 |
S.Rendine,
S.Pieraccini,
and
M.Sironi
(2010).
Vinblastine perturbation of tubulin protofilament structure: a computational insight.
|
| |
Phys Chem Chem Phys, 12,
15530-15536.
|
 |
|
|
|
|
 |
S.Yin,
R.Bhattacharya,
and
F.Cabral
(2010).
Human mutations that confer paclitaxel resistance.
|
| |
Mol Cancer Ther, 9,
327-335.
|
 |
|
|
|
|
 |
A.Cormier,
M.J.Clément,
M.Knossow,
S.Lachkar,
P.Savarin,
F.Toma,
A.Sobel,
B.Gigant,
and
P.A.Curmi
(2009).
The PN2-3 domain of centrosomal P4.1-associated protein implements a novel mechanism for tubulin sequestration.
|
| |
J Biol Chem, 284,
6909-6917.
|
 |
|
|
|
|
 |
A.L.Risinger,
F.J.Giles,
and
S.L.Mooberry
(2009).
Microtubule dynamics as a target in oncology.
|
| |
Cancer Treat Rev, 35,
255-261.
|
 |
|
|
|
|
 |
E.Wilcox,
C.McGrath,
A.V.Blokhin,
R.Gussio,
and
E.Hamel
(2009).
Evidence for a distinct ligand binding site on tubulin discovered through inhibition by GDP of paclitaxel-induced tubulin assembly in the absence of exogenous GTP.
|
| |
Arch Biochem Biophys, 484,
55-62.
|
 |
|
|
|
|
 |
J.Wang,
Y.Yin,
H.Hua,
M.Li,
T.Luo,
L.Xu,
R.Wang,
D.Liu,
Y.Zhang,
and
Y.Jiang
(2009).
Blockade of GRP78 sensitizes breast cancer cells to microtubules-interfering agents that induce the unfolded protein response.
|
| |
J Cell Mol Med, 13,
3888-3897.
|
 |
|
|
|
|
 |
M.C.Edler,
G.Yang,
M.Katherine Jung,
R.Bai,
W.G.Bornmann,
and
E.Hamel
(2009).
Demonstration of microtubule-like structures formed with (-)-rhazinilam from purified tubulin outside of cells and a simple tubulin-based assay for evaluation of analog activity.
|
| |
Arch Biochem Biophys, 487,
98.
|
 |
|
|
|
|
 |
N.L.Giles,
A.Armson,
and
S.A.Reid
(2009).
Characterization of trifluralin binding with recombinant tubulin from Trypanosoma brucei.
|
| |
Parasitol Res, 104,
893-903.
|
 |
|
|
|
|
 |
R.H.Dave,
W.Saengsawang,
J.Z.Yu,
R.Donati,
and
M.M.Rasenick
(2009).
Heterotrimeric G-proteins interact directly with cytoskeletal components to modify microtubule-dependent cellular processes.
|
| |
Neurosignals, 17,
100-108.
|
 |
|
|
|
|
 |
R.H.Wade
(2009).
On and around microtubules: an overview.
|
| |
Mol Biotechnol, 43,
177-191.
|
 |
|
|
|
|
 |
T.Manna,
D.A.Thrower,
S.Honnappa,
M.O.Steinmetz,
and
L.Wilson
(2009).
Regulation of microtubule dynamic instability in vitro by differentially phosphorylated stathmin.
|
| |
J Biol Chem, 284,
15640-15649.
|
 |
|
|
|
|
 |
A.Aggarwal,
A.Kruczynski,
A.Frankfurter,
J.J.Correia,
and
S.Lobert
(2008).
Murine leukemia P388 vinorelbine-resistant cell lines are sensitive to vinflunine.
|
| |
Invest New Drugs, 26,
319-330.
|
 |
|
|
|
|
 |
A.Cormier,
M.Marchand,
R.B.Ravelli,
M.Knossow,
and
B.Gigant
(2008).
Structural insight into the inhibition of tubulin by vinca domain peptide ligands.
|
| |
EMBO Rep, 9,
1101-1106.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
C.A.Moores,
and
R.A.Milligan
(2008).
Visualisation of a kinesin-13 motor on microtubule end mimics.
|
| |
J Mol Biol, 377,
647-654.
|
 |
|
|
|
|
 |
E.R.Miraldi,
P.J.Thomas,
and
L.Romberg
(2008).
Allosteric models for cooperative polymerization of linear polymers.
|
| |
Biophys J, 95,
2470-2486.
|
 |
|
|
|
|
 |
F.Devred,
P.O.Tsvetkov,
P.Barbier,
D.Allegro,
S.B.Horwitz,
A.A.Makarov,
and
V.Peyrot
(2008).
Stathmin/Op18 is a novel mediator of vinblastine activity.
|
| |
FEBS Lett, 582,
2484-2488.
|
 |
|
|
|
|
 |
F.L.Henriquez,
P.R.Ingram,
S.P.Muench,
D.W.Rice,
and
C.W.Roberts
(2008).
Molecular basis for resistance of acanthamoeba tubulins to all major classes of antitubulin compounds.
|
| |
Antimicrob Agents Chemother, 52,
1133-1135.
|
 |
|
|
|
|
 |
F.Zanella,
A.Rosado,
B.García,
A.Carnero,
and
W.Link
(2008).
Chemical genetic analysis of FOXO nuclear-cytoplasmic shuttling by using image-based cell screening.
|
| |
Chembiochem, 9,
2229-2237.
|
 |
|
|
|
|
 |
K.Saikrishnan,
S.P.Griffiths,
N.Cook,
R.Court,
and
D.B.Wigley
(2008).
DNA binding to RecD: role of the 1B domain in SF1B helicase activity.
|
| |
EMBO J, 27,
2222-2229.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
L.Hiser,
B.Herrington,
and
S.Lobert
(2008).
Effect of noscapine and vincristine combination on demyelination and cell proliferation in vitro.
|
| |
Leuk Lymphoma, 49,
1603-1609.
|
 |
|
|
|
|
 |
P.Singh,
K.Rathinasamy,
R.Mohan,
and
D.Panda
(2008).
Microtubule assembly dynamics: an attractive target for anticancer drugs.
|
| |
IUBMB Life, 60,
368-375.
|
 |
|
|
|
|
 |
T.M.Cao,
D.Durrant,
A.Tripathi,
J.Liu,
S.Tsai,
G.E.Kellogg,
D.Simoni,
and
R.M.Lee
(2008).
Stilbene derivatives that are colchicine-site microtubule inhibitors have antileukemic activity and minimal systemic toxicity.
|
| |
Am J Hematol, 83,
390-397.
|
 |
|
|
|
|
 |
Y.Yamazaki,
K.Kohno,
H.Yasui,
Y.Kiso,
M.Akamatsu,
B.Nicholson,
G.Deyanat-Yazdi,
S.Neuteboom,
B.Potts,
G.K.Lloyd,
and
Y.Hayashi
(2008).
Tubulin photoaffinity labeling with biotin-tagged derivatives of potent diketopiperazine antimicrotubule agents.
|
| |
Chembiochem, 9,
3074-3081.
|
 |
|
|
|
|
 |
B.Kappes,
and
P.Rohrbach
(2007).
Microtubule inhibitors as a potential treatment for malaria.
|
| |
Future Microbiol, 2,
409-423.
|
 |
|
|
|
|
 |
H.Yang,
and
F.Cabral
(2007).
Heightened sensitivity to paclitaxel in Class IVa beta-tubulin-transfected cells is lost as expression increases.
|
| |
J Biol Chem, 282,
27058-27066.
|
 |
|
|
|
|
 |
J.T.Huzil,
K.Chen,
L.Kurgan,
and
J.A.Tuszynski
(2007).
The Roles of beta-Tubulin Mutations and Isotype Expression in Acquired Drug Resistance.
|
| |
Cancer Inform, 3,
159-181.
|
 |
|
|
|
|
 |
T.Usui
(2007).
Actin- and microtubule-targeting bioprobes: their binding sites and inhibitory mechanisms.
|
| |
Biosci Biotechnol Biochem, 71,
300-308.
|
 |
|
|
|
|
 |
Y.Yan,
and
K.Broadie
(2007).
In vivo assay of presynaptic microtubule cytoskeleton dynamics in Drosophila.
|
| |
J Neurosci Methods, 162,
198-205.
|
 |
|
|
|
|
 |
Z.Wang,
P.A.McPherson,
B.S.Raccor,
R.Balachandran,
G.Zhu,
B.W.Day,
A.Vogt,
and
P.Wipf
(2007).
Structure-activity and high-content imaging analyses of novel tubulysins.
|
| |
Chem Biol Drug Des, 70,
75-86.
|
 |
|
|
|
|
 |
C.Marchand,
S.Antony,
K.W.Kohn,
M.Cushman,
A.Ioanoviciu,
B.L.Staker,
A.B.Burgin,
L.Stewart,
and
Y.Pommier
(2006).
A novel norindenoisoquinoline structure reveals a common interfacial inhibitor paradigm for ternary trapping of the topoisomerase I-DNA covalent complex.
|
| |
Mol Cancer Ther, 5,
287-295.
|
 |
|
|
|
|
 |
C.Martínez-Campa,
P.Casado,
R.Rodríguez,
P.Zuazua,
J.M.García-Pedrero,
P.S.Lazo,
and
S.Ramos
(2006).
Effect of vinca alkaloids on ERalpha levels and estradiol-induced responses in MCF-7 cells.
|
| |
Breast Cancer Res Treat, 98,
81-89.
|
 |
|
|
|
|
 |
E.J.Carpenter,
J.T.Huzil,
R.F.Ludueña,
and
J.A.Tuszynski
(2006).
Homology modeling of tubulin: influence predictions for microtubule's biophysical properties.
|
| |
Eur Biophys J, 36,
35-43.
|
 |
|
|
|
|
 |
E.Nogales,
and
H.W.Wang
(2006).
Structural intermediates in microtubule assembly and disassembly: how and why?
|
| |
Curr Opin Cell Biol, 18,
179-184.
|
 |
|
|
|
|
 |
E.Nogales,
and
H.W.Wang
(2006).
Structural mechanisms underlying nucleotide-dependent self-assembly of tubulin and its relatives.
|
| |
Curr Opin Struct Biol, 16,
221-229.
|
 |
|
|
|
|
 |
H.Ishikawa,
G.I.Elliott,
J.Velcicky,
Y.Choi,
and
D.L.Boger
(2006).
Total synthesis of (-)- and ent-(+)-vindoline and related alkaloids.
|
| |
J Am Chem Soc, 128,
10596-10612.
|
 |
|
|
|
|
 |
H.Morii,
Y.Shiraishi-Yamaguchi,
and
N.Mori
(2006).
SCG10, a microtubule destabilizing factor, stimulates the neurite outgrowth by modulating microtubule dynamics in rat hippocampal primary cultured neurons.
|
| |
J Neurobiol, 66,
1101-1114.
|
 |
|
|
|
|
 |
I.Divinski,
M.Holtser-Cochav,
I.Vulih-Schultzman,
R.A.Steingart,
and
I.Gozes
(2006).
Peptide neuroprotection through specific interaction with brain tubulin.
|
| |
J Neurochem, 98,
973-984.
|
 |
|
|
|
|
 |
S.Honnappa,
W.Jahnke,
J.Seelig,
and
M.O.Steinmetz
(2006).
Control of intrinsically disordered stathmin by multisite phosphorylation.
|
| |
J Biol Chem, 281,
16078-16083.
|
 |
|
|
|
|
 |
S.Sengupta,
and
S.A.Thomas
(2006).
Drug target interaction of tubulin-binding drugs in cancer therapy.
|
| |
Expert Rev Anticancer Ther, 6,
1433-1447.
|
 |
|
|
|
|
 |
Y.Pommier
(2006).
Topoisomerase I inhibitors: camptothecins and beyond.
|
| |
Nat Rev Cancer, 6,
789-802.
|
 |
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
codes are
shown on the right.
|
| |